LB Pharmaceuticals Q2 net loss widens on higher R&D costs
LBRX•Cash raise and outlook
LB Pharmaceuticals raised $150 million in a private placement to fund pipeline expansion.
The company expects its current cash position to fund operations beyond Q2 2029.
Clinical trial timeline and analyst coverage
LB Pharmaceuticals expects topline data from the Phase 3 NOVA-2 trial in schizophrenia in H1 2027.
The company anticipates topline data from the Phase 2 trial in bipolar depression in Q1 2028.
The current average analyst rating on the shares is "buy", with 9 "strong buy" or "buy" ratings, no "hold" and no "sell" or "strong sell". The average consensus recommendation for the biotechnology and medical research peer group is "buy".
Wall Street's median 12-month price target for LB Pharmaceuticals Inc is $45.00, about 1.9% below its August 10 closing price of $45.85.
